Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

has made significant headway in a project to develop its own CGM. In addition to DexCom (DXCM) and Abbott (ABT), Medtronic ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

DexCom's Q3 results showed disappointing 2% revenue growth and a 26% decline in operating income. Click here to read my DXCM ...

Remote monitoring for patients with implanted cardiac electrophysiology devices may finally be coming of age in the U.K. thanks to a review of these systems by the National Institute for Health and ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

RBC analysts are keen to learn more from Dexcom about CGM price and competition dynamics with Abbott. The devices from Recor and Medtronic are intended to treat high blood pressure. An advisory panel ...

Headquartered in Dublin, Ireland, Medtronic plc develops, manufactures ... On August 7, 2024, MDT announced FDA approval of its Simplera continuous glucose monitor (CGM) and a global partnership with ...

However, at Taiwan Innotech Expo 2024, the company Singular Wings Medical has shown off its non-invasive CGM that monitors blood sugar using – wait for it – an electrocardiogram, or ECG ...

Medtronic in Santa Ana says its layoffs would be temporary while it repairs the roof of its medical device-making facility, while Avante Health Solutions in San Clemente hopes to retain its staff ...